/PRNewswire/ UNION therapeutics A/S (UNION), a privately held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and.
NEW ORLEANS — Patients with psoriasis who had suboptimal results with prior interleukin-17 therapy experienced beneficial results with risankizumab, according to a presenter at the American Academy of Dermatology Annual Meeting.
“Within the real world, patients with residual disease really want to switch onto more effective therapy,” Richard B. Warren, MBChB, PhD, of the
FDA s Fast Track designation for oral orismilast underscores the urgent need for new treatment options to fulfil the unmet medical need for people affected by.
Primary endpoint at week 16 was met for all three active doses of oral orismilast in moderate to severe patients with psoriasis. Statistical significance.